Tecovirimat Ineffective for Mpox Symptom Relief, NIH Study Concludes
A study by the NIH found that the antiviral drug tecovirimat was safe but did not improve lesion resolution or pain in adults with mild to moderate clade II mpox. The study, part of the STOMP trial, led to the recommendation to stop further enrollment due to lack of efficacy. The trial highlighted the importance of well-designed clinical trials during outbreaks and will inform future mpox treatments. Tecovirimat was initially approved for smallpox, and its efficacy for mpox remains unproven.